Diabetic Neuropathy Market Report 2026

The diabetic neuropathy market size has grown strongly in recent years. It will grow from $6.21 billion in 2025 to $6.83 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to long-term uncontrolled diabetes prevalence, delayed diagnosis of nerve damage, limited treatment options, reliance on pain management therapies, rising patient discomfort.

The diabetic neuropathy market size is expected to see rapid growth in the next few years. It will grow to $10.14 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to development of targeted neuropathy drugs, expansion of early diagnostic tools, increasing patient screening, growth in specialty neurology clinics, demand for improved quality of life. Major trends in the forecast period include increasing use of neuropathic pain medications, rising focus on early nerve damage detection, expansion of combination drug therapies, growing adoption of symptom management approaches, increased patient awareness and diagnosis rates.

The growing prevalence of diabetes is expected to drive the expansion of the diabetic neuropathy market in the coming years. Diabetes is a chronic condition in which the body is unable to properly regulate or utilize glucose due to insufficient insulin production or ineffective insulin use. Diabetic neuropathy is a form of nerve damage that develops in individuals with diabetes and can involve different types of nerve impairment, resulting in varied symptoms. For instance, in April 2025, according to the International Diabetes Federation, a Belgium-based international non-profit organization representing national diabetes associations, approximately 589 million adults aged 20-79 were living with diabetes worldwide, with this figure projected to rise to 853 million by 2050. Therefore, the increasing prevalence of diabetes is driving the growth of the diabetic neuropathy market.

Major companies operating in the diabetic neuropathy market are advancing innovative treatment options, such as neuromodulation therapy devices, to improve pain management for patients experiencing chronic diabetic neuropathy. Neuromodulation therapy devices provide non-invasive treatment by altering nerve activity to reduce pain, enhance nerve function, and support healing in patients with diabetic nerve damage. For instance, in January 2024, Neuralace Medical Inc., a US-based provider of non-drug pain management solutions, received approval from the U.S. Food and Drug Administration (FDA) for its Axon Therapy device for the treatment of chronic painful diabetic neuropathy. The Axon Therapy device uses neuromodulation techniques to relieve pain associated with diabetic neuropathy, representing a significant advancement in therapeutic options. The FDA clearance confirms the device’s safety and effectiveness, enabling commercialization and broader patient access.

In December 2023, Celeri Research Group, a US-based clinical research and real-world evidence company, partnered with Averitas Pharma Inc. to conduct a post-market, multicenter observational study evaluating treatment outcomes in neuropathic pain. Through this collaboration, the companies aim to generate real-world evidence on the effectiveness of the QUTENZA high-concentration capsaicin patch in adults with painful diabetic peripheral neuropathy, enhance understanding of patient-reported outcomes, and support long-term improvements in neuropathic pain management. Averitas Pharma Inc. is a US-based specialty pharmaceutical company focused on non-opioid therapies for neuropathic and chronic pain conditions.

Major companies operating in the diabetic neuropathy market are Pfizer Inc., Eli Lilly and Company, Daiichi Sankyo Company Limited, Johnson & Johnson, Depomed Inc., F. Hoffmann-La Roche AG, NeuroMetrix Inc, Lupin Limited, Novartis AG, Boehringer Ingelheim, Regenacy Pharmaceuticals Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Merck KGaA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Zydus Cadila, Genentech Inc.

North America was the largest region in the diabetic neuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the diabetic neuropathy market during the forecast period. The regions covered in the diabetic neuropathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetic neuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diabetic neuropathy market by increasing costs of imported medications, diagnostic devices, and neurological testing equipment. Hospitals and specialty clinics in developed regions are most affected due to reliance on imported drugs, while emerging markets face affordability challenges. These tariffs increase treatment costs. However, they are encouraging domestic drug production and regional sourcing of diagnostic tools.

The diabetic neuropathy market research report is one of a series of new reports that provides diabetic neuropathy market statistics, including diabetic neuropathy industry global market size, regional shares, competitors with a diabetic neuropathy market share, detailed diabetic neuropathy market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic neuropathy industry. This diabetic neuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetic neuropathy is a form of nerve damage that can develop in individuals with diabetes. It is caused by prolonged high blood sugar levels, which can damage blood vessels and impair nerve function. This condition can affect various nerves throughout the body, including those in the feet, internal organs, and muscles.

The main types of diabetic neuropathy include peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. Peripheral neuropathy occurs when the peripheral nerves responsible for transmitting signals between the brain, spinal cord, and the rest of the body are damaged. The primary drug classes used to manage diabetic neuropathy include analgesics, antidepressants, anticonvulsants, and others, along with treatment approaches such as drug therapy, radiotherapy, physiotherapy, and additional modalities. These treatments are distributed through both online and offline channels and are utilized in hospitals, specialty clinics, and other healthcare settings.

The diabetic neuropathy market consists of sales of drugs such as anticonvulsants, pain medications, nerve growth factor inhibitors and other drugs that are used to treat the symptoms of nerve damage caused by diabetes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.